XRCC 1194Arg/Trp基因多态与晚期乳腺癌患者铂类方案近期疗效的相关研究  

Association between Polymorphism in XRCC1 194Arg/Trp and the Efficacy of Platinum-based Chemotherapy in Recurrent or Metastatic Breast Cancer Patients

作　　者：廖瑜倩[1] 万以叶[1] 彭丽香[1] 芦珊[1] 

机构地区：[1]江西省肿瘤医院,330029

出　　处：《实用癌症杂志》2012年第6期568-571,共4页The Practical Journal of Cancer

基　　金：江西省科技厅科技支撑项目(编号2010BSA13800)

摘　　要：目的研究XRCC1 194Arg/Trp基因多态与晚期乳腺癌铂类方案近期疗效的关系。方法 56例晚期乳腺癌患者接受含铂类方案一线治疗,分析XRCC1 194Arg/Trp基因多态与患者临床获益率及无进展生存期的相关性。结果Arg/Arg、Arg/Trp和Trp/Trp基因型临床获益组和非临床获益组分布频率分别为30.6%、55.6%、13.8%和55.0%、35.0%、10.0%。Trp/Trp+Arg/Trp基因型患者临床获益率高于Arg/Arg型患者,分别为73.5%和50.0%,经年龄、术时分期校正后,P=0.055。Trp/Trp+Arg/Trp及Arg/Arg基因型患者2年无进展生存率分别为43.5%和34.1%,无显著性差异(P=0.460)。结论 XRCC1 194Arg/Trp基因多态可能成为晚期乳腺癌患者铂类方案治疗效果的预测指标。Objective To investigate the association between polymorphism in XRCC1 194Arg/Trp and the efficacy of platinum in recurrent or metastatic breast cancer patients.Methods 56 patients with recurrent or metastatic breast cancer treated with platinum-based chemotherapy were enrolled.Polymerase chain reaction based restriction fragment length polymorphism assay was used to determine the genotypes.Results The frequencies of Arg/Arg,Arg/Trp and Trp/Trp genotypes were 30.6%,55.6% and 13.8% in patients with clinical benefits and 55.0%,35.0% and 10.0% in patients without clinical benefits,respectively.The clinical benefit rate was higher in patients with Trp/Trp＋Arg/Trp genotypes than in patients with Arg/Arg genotype,73.5% vs 50.0%.After adjusted by age and stage,the P value was borderline（P=0.055）.The 2-year＇s progression-free survival rate in patients with Trp/Trp＋Arg/Trp genotypes and Arg/Arg genotype were 43.5% and 34.1%,respectively（P=0.460）.Conclusion These results suggested that XRCC1 194Arg/Trp might be a predictor of the sensitivity of platinum-based chemotherapy.

关 键 词：XRCC1 基因多态 铂类 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]